Lv2
128 积分 2022-04-14 加入
Preclinical and First-in-Human Study of Carbonic Anhydrase IX–Targeting Theranostic Pair, [ 68 Ga]Ga/[ 177 Lu]Lu-NYM096, in Clear Cell Renal Cell Carcinoma
1个月前
已完结
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
3个月前
已完结
Hormonal Agents in Localized and Advanced Prostate Cancer: Current Use and Future Perspectives
6个月前
已完结
Recent update on the development of EZH2 inhibitors and degraders for cancer therapy
6个月前
已完结
EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models
6个月前
已完结
Reversing—or Rewiring—Lineage Plasticity? Lessons from EZH2 Loss in Prostate Cancer
6个月前
已完结
EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
7个月前
已完结
Combining PSMA-Targeted Radiopharmaceutical Therapy with Immunotherapy
8个月前
已完结
A Comprehensive Systematic Review and Meta-analysis of the Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Diagnosis and Primary Staging before Definitive Treatment
11个月前
已完结
Targeting the tumour cell surface in advanced prostate cancer
11个月前
已完结
皖公网安备34019202002308
